Our data show that global pharma M&A is becoming more selective and strategically targeted. While North America remains the ...

The worlds of technology and entrepreneurship are captivated by recent advances in generative AI and large language models (LLMs). But if the future has arrived, as science fiction writer William ...

In today’s digitally transformed world, technology plays a critical role in how pharmaceutical companies do business. From drug discovery to manufacturing and commercialization, technology is powering ...

BostonGene has won four awards in the Research & Development, Product Launches, and Innovation categories in the 2025 Pharmaceutical Technology Excellence Awards.

The specialty pharmacy industry is in a state of transformation, fueled by the rise of complex, innovative therapies and the critical need for more robust patient support. For too long, specialty ...

The year 2025 was defined by escalating global trade tensions that fundamentally reshaped the pharmaceutical supply chain, ...

Define Ventures’ new report provides a clear framework for how enterprise healthcare, particularly Big Pharma, is transitioning from AI exploration to execution. It focuses on core categories, ...

Eli Lilly’s market capitalisation hit the $1tn mark in the past week, becoming the first healthcare company in the world to join the exclusive club dominated by technology companies. Buoyed by ...

DUBLIN--(BUSINESS WIRE)--The "Royalty Rates in Pharmaceutical and Biotechnology Deals" report has been added to ResearchAndMarkets.com's offering. Royalty Rates in Pharmaceutical and Biotechnology ...

New food and beverage applications have been demonstrated for a whole host of bioactive botanical ingredients via a new dispersal technology. The technology was presented to the market at the recent ...

NEW YORK, Feb. 20, 2025 /PRNewswire/ -- Hong Kong Pharma Digital Technology Holdings Limited has recently signed a cooperation agreement with a leading technology-driven e-commerce platform serving ...

With the latest batch’s agreements, only three out of the 17 drugmakers initially targeted by Trump have not signed pricing ...